title: Pilot safety study of low-dose vasopressin in non-septic critically ill children.
abstract: OBJECTIVE
  To assess the safety of low-dose vasopressin infusion in critically ill children requiring prolonged mechanical ventilation (MV) at risk of developing sedation/analgesia-related hypotension.
  
  
  METHODS
  Randomized pilot safety study in children expected to require MV for at least 3 days. Children received either vasopressin (0.0005 U/kg/min) or sodium chloride (0.9%) infusion for a period of 48 h. Haemodynamic variables, urine output and serum electrolytes were closely monitored and analyzed.
  
  
  RESULTS
  Twelve children in each group had similar baseline characteristics. Vasopressin infusion was associated with an 8 mmol/L fall in serum sodium concentration (p < 0.01) and with higher incidence of hyponatraemia (8 vs. 66%, p < 0.01). In normotensive children, low-dose vasopressin also induced a reversible decrease in urine output, and acutely increased blood pressure (p < 0.01). After stopping the vasopressin there was rebound hypotension (p < 0.01).
  
  
  CONCLUSIONS
  Low-dose vasopressin infusion in haemodynamically stable, but critically ill, children is associated with reduction in urine output and decreased serum sodium level, yielding a high incidence of hyponatraemia. We conclude that these effects limit further study of prophylactic vasopressin for sedation-related hypotension in a randomized controlled trial.
authors.affiliation: Pediatric Intensive Care Unit, Department of Pediatrics, Hospital São Lucas da PUCRS, Porto Alegre, Brazil.
authors.forename: Elisa
authors.initials: E
authors.lastname: Baldasso
authors.forename: Pedro Celiny Ramos
authors.initials: PC
authors.lastname: Garcia
authors.forename: Jefferson Pedro
authors.initials: JP
authors.lastname: Piva
authors.forename: Ricardo Garcia
authors.initials: RG
authors.lastname: Branco
authors.forename: Robert Charles
authors.initials: RC
authors.lastname: Tasker
mesh_terms: D016638:Critical Illness; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D007010:Hyponatremia / Q000097:blood; D007022:Hypotension / Q000188:drug therapy* / Q000453:epidemiology; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D010865:Pilot Projects; D012121:Respiration, Artificial; D012131:Respiratory Insufficiency / Q000453:epidemiology / Q000628:therapy; D012965:Sodium Chloride / Q000097:blood; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D014662:Vasoconstrictor Agents; D012965:Sodium Chloride